Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00027314
DRKS00027314
Recruiting
Not Applicable

ongitudinal study of immune response and epigenetics in acute LongCovid syndrome secondary to COVID-19 disease.

Klinik I für Innere MedizinUniversitätsklinikum Köln (AöR)0 sites100 target enrollmentJanuary 2, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionspost-COVID-19 syndromeU09.9Post COVID-19 condition, unspecified

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
post-COVID-19 syndrome
Sponsor
Klinik I für Innere MedizinUniversitätsklinikum Köln (AöR)
Enrollment
100
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 2, 2023
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Klinik I für Innere MedizinUniversitätsklinikum Köln (AöR)

Eligibility Criteria

Inclusion Criteria

  • •Good physical condition (Karnofsky index \=80%).
  • •Previous laboratory diagnostic evidence of SARS\-CoV\-2 infection.
  • •Current existing LongCovid syndrome.

Exclusion Criteria

  • •Hemoglobin \<10 g/dL
  • •Symptomatic heart disease (e.g., heart failure NYHA \=II, coronary artery disease)
  • •previous myocardial infarction
  • •COPD Stage GOLD III\-IV
  • •Body weight less than 45kg
  • •\<8 weeks (men) or \<12 weeks (women) since last blood collection of \=500 ml

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Characterisation of COVID-19 long-term immunityCOVID-19 (SARS-CoV-2 infection)Infections and Infestations
ISRCTN11946807niversity of Bristol372
Completed
Not Applicable
Exposure in Epigenetic Regulation of Immune Response in Chronic Beryllium Disease (CBD)Chronic Beryllium Disease
NCT02604693National Jewish Health148
Not yet recruiting
Not Applicable
Study to the humoral and cellular immuneresponse after influenzavaccination in patients with metastasized RCC or GIST treated with a tyrosine kinase inhibitor(sunitinib or sorafenib)GISTkidney cancer10038363
NL-OMON32710niversitair Medisch Centrum Sint Radboud75
Recruiting
Phase 4
Immune response after two doses of COVID-19 vaccinatioCoronavirus Disease 2019D000086382
JPRN-jRCT1051210161Kayeka Hiroshi600
Active, not recruiting
Not Applicable
A study of humoral and cellular-mediated immune response in Monoclonal gammopathy of Undetermined Significance after vaccination with trivalent inactivated influenza vaccine (influvac) - mgus-vacc respons
EUCTR2010-022693-14-NLuniversity medical centre groningen